Guidelines
Early Access
The Italian Society for Rheumatology guidelines for the treatment of patients with rheumatoid arthritis and interstitial lung disease
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Published: 10 November 2025
492
Views
127
Downloads
Authors
Objective. In the absence of national and European guidelines on the treatment of rheumatoid arthritis (RA) with interstitial lung disease (ILD), the Italian Society of Rheumatology decided to develop national clinical practice guidelines on the management of patients with RA-ILD in accordance with the requirements of the National Guideline System of the National Institute of Health.
Methods. The development process included a systematic review of the available evidence and its adaptability to the Italian context, followed by a consultation with experts in rheumatology, respiratory diseases, radiology, and representatives of the health professions and patients.
Results. The panel decided to develop recommendations in three main scenarios. The first section of recommendations is focused on drugs indicated for RA to assess their safety and efficacy in RA-ILD. The second set of recommendations covered the drugs indicated for the treatment of ILD in patients with RA-ILD (to assess their efficacy and safety in patients with RA). The third part of these guidelines dealt with drugs indicated for the treatment of RA-ILD upon first-line failure. Moreover, the lack or absence of scientific evidence in literature on certain topics, such as the value of a multidisciplinary treatment approach and lung transplantation, led to the decision to proceed through expert consensus to develop good clinical practice guidelines.
Conclusions. These guidelines represent a fundamental step towards improving the health management of patients with rheumatological diseases in Italy by providing specific and evidence-based guidelines for the management of RA-ILD. Their use is intended to promote health and reduce the burden of morbidity and mortality in this vulnerable population.
Downloads
Download data is not yet available.
Citations
Salaffi F, De Angelis R, Grassi W, MArche Pain Prevalence, INvestigation Group (MAPPING) study. Prevalence of musculoskeletal conditions in an Italian population sample: results of a regional community-based study. I. The MAPPING study. Clin Exp Rheumatol 2005; 23: 819-28.
Rossini M, Rossi E, Bernardi D, Viapiana O, Gatti D, Idolazzi L, et al. Prevalence and incidence of rheumatoid arthritis in Italy. Rheumatol Int 2014; 34: 659-64. DOI: https://doi.org/10.1007/s00296-014-2974-6
Juge PA, Crestani B, Dieude P. Recent advances in rheumatoid arthritis-associated interstitial lung disease. Curr Opin Pulm Med 2020; 26: 477-86. DOI: https://doi.org/10.1097/MCP.0000000000000710
Samhouri BF, Vassallo R, Achenbach SJ, Kronzer VL, Davis JM 3rd, Myasoedova E, et al. Incidence, risk factors, and mortality of clinical and subclinical rheumatoid arthritis-associated interstitial lung disease: a population-based cohort. Arthritis Care Res 2022; 74: 2042-9. DOI: https://doi.org/10.1002/acr.24856
Raimundo K, Solomon JJ, Olson AL, Kong AM, Cole AL, Fischer A, et al. Rheumatoid arthritis-interstitial lung disease in the United States: prevalence, incidence, and healthcare costs and mortality. J Rheumatol 2019; 46: 360-9. DOI: https://doi.org/10.3899/jrheum.171315
Manfredi A, Cassone G, Luppi F, Atienza-Mateo B, Cavazza A, Sverzellati N, et al. Rheumatoid arthritis related interstitial lung disease. Expert Rev Clin Immunol 2021; 17: 485-97. DOI: https://doi.org/10.1080/1744666X.2021.1905524
Narvaez J, Diaz Del Campo Fontecha P, Brito Garcia N, Bonilla G, Aburto M, Castellvi I, et al. SER-SEPAR recommendations for the management of rheumatoid arthritis-related interstitial lung disease. Part 2: Treatment. Reumatol Clin 2022; 18: 501-12. DOI: https://doi.org/10.1016/j.reumae.2022.03.004
Johnson SR, Bernstein EJ, Bolster MB, Chung JH, Danoff SK, George MD, et al. 2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Treatment of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases. Arthritis Rheumatol 2024; 76: 1182-200. DOI: https://doi.org/10.1002/art.42861
Boutel M, Boutou A, Pitsiou G, Garyfallos A, Dimitroulas T. Efficacy and safety of nintedanib in patients with connective tissue disease-interstitial lung disease (CTD-ILD): a real-world single center experience. Diagnostics 2023; 13: 1221. DOI: https://doi.org/10.3390/diagnostics13071221
Dellaripa P AM, Hoffmann-Vold A, Kelly C, Mittoo S, James A, et al. Effects of nintedanib in patients with progressive fibrosing autoimmune disease-related interstitial lung diseases (ILDs) in the INBUILD trial: subgroups by HRCT pattern. Arthritis Rheumatol 2020; 72: 2106‐7.
Flaherty KR, Wells AU, Cottin V, Devaraj A, Walsh SLF, Inoue Y, et al. Nintedanib in progressive fibrosing interstitial lung diseases. N Engl J Med 2019; 381: 1718-27. DOI: https://doi.org/10.1056/NEJMoa1908681
Solomon JJ, Danoff SK, Woodhead FA, Hurwitz S, Maurer R, Glaspole I, et al. Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: a randomised, double-blind, placebo-controlled, phase 2 study. Lancet Respir Med 2023; 11: 87-96. DOI: https://doi.org/10.1016/j.chest.2021.12.293
Smolen JS, Landewe RBM, Bergstra SA, Kerschbaumer A, Sepriano A, Aletaha D, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis 2023; 82: 3-18. DOI: https://doi.org/10.1136/ard-2022-223356corr1
Schunemann HJ, Wiercioch W, Brozek J, Etxeandia-Ikobaltzeta I, Mustafa RA, Manja V, et al. GRADE Evidence to Decision (EtD) frameworks for adoption, adaptation, and de novo development of trustworthy recommendations: GRADE-ADOLOPMENT. J Clin Epidemiol 2017; 81: 101-10. DOI: https://doi.org/10.1016/j.jclinepi.2016.09.009
SNLG. Manuale metodologico per la produzione di linee guida di pratica clinica. Available from: https://www.iss.it/-/snlg-strumenti-per-i-produttori.
CNEC. Manuale operativo per la produzione di linee guida di pratica clinica. 2020. Available from: https://www.iss.it/documents/20126/7949265/Manuale+Operativo+-+Marzo+2023.pdf/a5e90b61-da08-d136-9107-0d456aacddb5?t=1679921975702.
SIR. Le raccomandazioni della Società Italiana di Reumatologia sul trattamento del paziente con artrite reumatoide e interstiziopatia polmonare. Available from: https://www.iss.it/documents/20126/9466951/LG_C0027_SIR+AR-IP.pdf/8f6af563-07db-fe82-7015-386e94573991?t=1729601917500.
ACR. Interstitial lung disease clinical practice guidelines - project plan 2023. Available from: https://assets.contentstack.io/v3/assets/bltee37abb6b278ab2c/blt4997854b4055c262/632e223f763d011cd3e9249b/interstitial-lung-disease-guideline-project-plan-2023.pdf.
Dewidar O, Lotfi T, Langendam MW, Parmelli E, Saz Parkinson Z, Solo K, et al. Good or best practice statements: proposal for the operationalisation and implementation of GRADE guidance. BMJ Evid Based Med 2023; 28: 189-96. DOI: https://doi.org/10.1136/bmjebm-2022-111962
Sterne JA, Hernan MA, Reeves BC, Savovic J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ 2016; 355: i4919. DOI: https://doi.org/10.1136/bmj.i4919
Sterne JAC, Savovic J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 2019; 366: l4898. DOI: https://doi.org/10.1136/bmj.l4898
Makarski J, Brouwers MC, Enterprise A. The AGREE Enterprise: a decade of advancing clinical practice guidelines. Implement Sci 2014; 9: 103. DOI: https://doi.org/10.1186/s13012-014-0103-2
Kim K, Woo A, Park Y, Yong SH, Lee SH, Lee SH, et al. Protective effect of methotrexate on lung function and mortality in rheumatoid arthritis-related interstitial lung disease: a retrospective cohort study. Ther Adv Respir Dis 2022; 16: 17534666221135314. DOI: https://doi.org/10.1177/17534666221135314
Rojas-Serrano J, Herrera-Bringas D, Perez-Roman DI, Perez-Dorame R, Mateos-Toledo H, Mejia M. Rheumatoid arthritis-related interstitial lung disease (RA-ILD): methotrexate and the severity of lung disease are associated to prognosis. Clin Rheumatol 2017; 36: 1493-500. DOI: https://doi.org/10.1007/s10067-017-3707-5
Makino H, Kotani T, Hata K, Nishioka D, Yamamoto W, Yoshikawa A, et al. Prognostic factors affecting respiratory-related death in patients with rheumatoid arthritis complicated by interstitial lung disease: an ANSWER cohort study. Mod Rheumatol 2023; 33: 928-35. DOI: https://doi.org/10.1093/mr/roac115
Izuka S, Yamashita H, Iba A, Takahashi Y, Kaneko H. Acute exacerbation of rheumatoid arthritis-associated interstitial lung disease: clinical features and prognosis. Rheumatology 2021; 60: 2348-54. DOI: https://doi.org/10.1093/rheumatology/keaa608
Cano-Jimenez E, Vazquez Rodriguez T, Martin-Robles I, Castillo Villegas D, Juan Garcia J, Bollo de Miguel E, et al. Diagnostic delay of associated interstitial lung disease increases mortality in rheumatoid arthritis. Sci Rep 2021; 11: 9184. DOI: https://doi.org/10.1038/s41598-021-88734-2
Kim JW, Chung SW, Pyo JY, Chang SH, Kim MU, Park CH, et al. Methotrexate, leflunomide and tacrolimus use and the progression of rheumatoid arthritis-associated interstitial lung disease. Rheumatology 2023; 62: 2377-85. DOI: https://doi.org/10.1093/rheumatology/keac651
Matson SM, Baqir M, Moua T, Marll M, Kent J, Iannazzo NS, et al. Treatment outcomes for rheumatoid arthritis-associated interstitial lung disease: a real-world, multisite study of the impact of immunosuppression on pulmonary function trajectory. Chest 2023; 163: 861-9. DOI: https://doi.org/10.1016/j.chest.2022.11.035
Fraenkel L, Bathon JM, England BR, St Clair EW, Arayssi T, Carandang K, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res 2021; 73: 924-39. DOI: https://doi.org/10.1002/acr.24596
Parisi S, Bortoluzzi A, Sebastiani GD, Conti F, Caporali R, Ughi N, et al. The Italian Society for Rheumatology clinical practice guidelines for rheumatoid arthritis. Reumatismo 2019; 71: 22-49. DOI: https://doi.org/10.4081/reumatismo.2019.1202
Antoniou KM, Mamoulaki M, Malagari K, Kritikos HD, Bouros D, Siafakas NM, et al. Infliximab therapy in pulmonary fibrosis associated with collagen vascular disease. Clin Exp Rheumatol 2007; 25: 23-8.
Curtis JR, Sarsour K, Napalkov P, Costa LA, Schulman KL. Incidence and complications of interstitial lung disease in users of tocilizumab, rituximab, abatacept and anti-tumor necrosis factor alpha agents, a retrospective cohort study. Arthritis Res Ther 2015; 17: 319. DOI: https://doi.org/10.1186/s13075-015-0835-7
Koo BS, Hong S, Kim YJ, Kim YG, Lee CK, Yoo B. Mortality in patients with rheumatoid arthritis-associated interstitial lung disease treated with an anti-tumor necrosis factor agent. Korean J Intern Med 2015; 30: 104-9. DOI: https://doi.org/10.3904/kjim.2015.30.1.104
Nakashita T, Ando K, Kaneko N, Takahashi K, Motojima S. Potential risk of TNF inhibitors on the progression of interstitial lung disease in patients with rheumatoid arthritis. BMJ Open 2014; 4: e005615. DOI: https://doi.org/10.1136/bmjopen-2014-005615
Atienza-Mateo B, Fernandez-Diaz C, Vicente-Rabaneda EF, Melero-Gonzalez RB, Ortiz-Sanjuan F, Casafont-Sole I, et al. Abatacept in usual and in non-specific interstitial pneumonia associated with rheumatoid arthritis. Eur J Intern Med 2024; 119: 118-24. DOI: https://doi.org/10.1016/j.ejim.2023.08.025
Cassone G, Manfredi A, Atzeni F, Venerito V, Vacchi C, Picerno V, et al. Safety of abatacept in Italian patients with rheumatoid arthritis and interstitial lung disease: a multicenter retrospective study. J Clin Med 2020; 9: 277. DOI: https://doi.org/10.3390/jcm9010277
Fernandez-Diaz C, Castaneda S, Melero-Gonzalez RB, Ortiz-Sanjuan F, Juan-Mas A, Carrasco-Cubero C, et al. Abatacept in interstitial lung disease associated with rheumatoid arthritis: national multicenter study of 263 patients. Rheumatology 2020; 59: 3906-16.
Tardella M, Di Carlo M, Carotti M, Giovagnoni A, Salaffi F. Abatacept in rheumatoid arthritis-associated interstitial lung disease: short-term outcomes and predictors of progression. Clin Rheumatol 2021; 40: 4861-7. DOI: https://doi.org/10.1007/s10067-021-05854-w
Mochizuki T, Ikari K, Yano K, Sato M, Okazaki K. Long-term deterioration of interstitial lung disease in patients with rheumatoid arthritis treated with abatacept. Mod Rheumatol 2019; 29: 413-7. DOI: https://doi.org/10.1080/14397595.2018.1481566
Kurata I, Tsuboi H, Terasaki M, Shimizu M, Toko H, Honda F, et al. Effect of biological disease-modifying anti-rheumatic drugs on airway and interstitial lung disease in patients with rheumatoid arthritis. Intern Med 2019; 58: 1703-12. DOI: https://doi.org/10.2169/internalmedicine.2226-18
Tardella M, Di Carlo M, Carotti M, Ceccarelli L, Giovagnoni A, Salaffi F. A retrospective study of the efficacy of JAK inhibitors or abatacept on rheumatoid arthritis-interstitial lung disease. Inflammopharmacology 2022; 30: 705-12. DOI: https://doi.org/10.1007/s10787-022-00936-w
Lee KA, Kim BY, Kim SS, Cheon YH, Lee SI, Kim SH, et al. Effect of abatacept versus conventional synthetic disease modifying anti-rheumatic drugs on rheumatoid arthritis-associated interstitial lung disease. Korean J Intern Med 2024; 39: 855-64. DOI: https://doi.org/10.3904/kjim.2023.207
Atienza-Mateo B, Remuzgo-Martinez S, Prieto-Pena D, Mora Cuesta VM, Iturbe-Fernandez D, Llorca J, et al. Rituximab in the Treatment of interstitial lung disease associated with autoimmune diseases: experience from a single referral center and literature review. J Clin Med 2020; 9: 3070. DOI: https://doi.org/10.3390/jcm9103070
Chartrand S, Swigris JJ, Peykova L, Fischer A. Rituximab for the treatment of connective tissue disease- associated interstitial lung disease. Sarcoidosis Vasc Diffuse Lung Dis 2015; 32; 296-304.
Sahin Eroglu D, Colaklar A, Baysal S, Torgutalp M, Baygul A, Yayla ME, et al. Rituximab experience from a single centre for patients with rheumatoid arthritis-related interstitial lung disease. Sarcoidosis Vasc Diffuse Lung Dis 2022; 39: e2022029.
Fui A, Bergantini L, Selvi E, Mazzei MA, Bennett D, Pieroni MG, et al. Rituximab therapy in interstitial lung disease associated with rheumatoid arthritis. Intern Med J 2020; 50: 330-6. DOI: https://doi.org/10.1111/imj.14306
Matteson EL BT, Ryu JH, Crowson CS, Hartman TE, Dellaripa PF. Open-label, pilot study of the safety and clinical effects of rituximab in patients with rheumatoid arthritis-associated interstitial pneumonia. OJRA 2012; 2: 53-8. DOI: https://doi.org/10.4236/ojra.2012.23011
Narvaez J, Robles-Perez A, Molina-Molina M, Vicens-Zygmunt V, Luburich P, Yanez MA, et al. Real-world clinical effectiveness of rituximab rescue therapy in patients with progressive rheumatoid arthritis-related interstitial lung disease. Semin Arthritis Rheum 2020; 50: 902-10. DOI: https://doi.org/10.1016/j.semarthrit.2020.08.008
Akiyama M, Kaneko Y, Yamaoka K, Kondo H, Takeuchi T. Association of disease activity with acute exacerbation of interstitial lung disease during tocilizumab treatment in patients with rheumatoid arthritis: a retrospective, case-control study. Rheumatol Int 2016; 36: 881-9. DOI: https://doi.org/10.1007/s00296-016-3478-3
Manfredi A, Cassone, G., Furini F, Gremese E, Venerito V, Atzeni F, et al. Tocilizumab therapy in rheumatoid arthritis with interstitial lung disease: a multicentre retrospective study. Intern Med J 2020; 50: 1085-90. DOI: https://doi.org/10.1111/imj.14670
Kalyoncu U, Bilgin E, Erden A, Satis H, Tufan A, Tekgoz E, et al. Efficacy and safety of tofacitinib in rheumatoid arthritis-associated interstitial lung disease: TReasure real-life data. Clin Exp Rheumatol 2022; 40: 2071-7. DOI: https://doi.org/10.21203/rs.3.rs-903223/v1
Venerito V, Manfredi A, Carletto A, Gentileschi S, Atzeni F, Guiducci S, et al. Evolution of rheumatoid-arthritis-associated interstitial lung disease in patients treated with JAK inhibitors: a retrospective exploratory study. J Clin Med 2023; 12: 957. DOI: https://doi.org/10.3390/jcm12030957
Fischer A, Brown KK, Du Bois RM, Frankel SK, Cosgrove GP, Fernandez-Perez ER, et al. Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease. J Rheumatol 2013; 40: 640-6. DOI: https://doi.org/10.3899/jrheum.121043
Nakamura K, Ohbe H, Ikeda K, Uda K, Furuya H, Furuta S, et al. Intravenous cyclophosphamide in acute exacerbation of rheumatoid arthritis-related interstitial lung disease: a propensity-matched analysis using a nationwide inpatient database. Semin Arthritis Rheum 2021; 51: 977-82. DOI: https://doi.org/10.1016/j.semarthrit.2021.07.008
Liu L, Fang C, Sun B, Bao R, Zhang H. Predictors of progression in rheumatoid arthritis-associated interstitial lung disease: a single-center retrospective study from China. Int J Rheum Dis 2022; 25: 795-802. DOI: https://doi.org/10.1111/1756-185X.14351
Dixon WG, Hyrich KL, Watson KD, Lunt M, Consortium BCC, Symmons DP, et al. Influence of anti-TNF therapy on mortality in patients with rheumatoid arthritis-associated interstitial lung disease: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2010; 69: 1086-91. DOI: https://doi.org/10.1136/ard.2009.120626
Perez-Alvarez R, Perez-de-Lis M, Diaz-Lagares C, Pego-Reigosa JM, Retamozo S, Bove A, et al. Interstitial lung disease induced or exacerbated by TNF-targeted therapies: analysis of 122 cases. Semin Arthritis Rheum 2011; 41: 256-64. DOI: https://doi.org/10.1016/j.semarthrit.2010.11.002
Fernandez-Diaz C CS, Melero R, Loricera J, Ortiz-Sanjuan F, Juan-Mas A, et al. Abatacept in combination with metotrexate in patients with rheumatoid arthritis associated to interstitial lung disease: National multicenter study of 263 patients. Rheumatology 2020; 59: 3906-16. DOI: https://doi.org/10.1093/rheumatology/keaa621
Vicente-Rabaneda EF, Atienza-Mateo B, Blanco R, Cavagna L, Ancochea J, Castaneda S, et al. Efficacy and safety of abatacept in interstitial lung disease of rheumatoid arthritis: a systematic literature review. Autoimmun Rev 2021; 20: 102830. DOI: https://doi.org/10.1016/j.autrev.2021.102830
Rojas-Serrano J, Gonzalez-Velasquez E, Mejia M, Sanchez-Rodriguez A, Carrillo G. Interstitial lung disease related to rheumatoid arthritis: evolution after treatment. Reumatol Clin 2012; 8: 68-71. DOI: https://doi.org/10.1016/j.reuma.2011.12.008
Matteson EL, Aringer M, Burmester GR, Mueller H, Moros L, Kolb M. Effect of nintedanib in patients with progressive pulmonary fibrosis associated with rheumatoid arthritis: data from the INBUILD trial. Clin Rheumatol 2023; 42: 2311-9. DOI: https://doi.org/10.1007/s10067-023-06623-7
Wang J, Wang X, Qi X, Sun Z, Zhang T, Cui Y, et al. The efficacy and safety of pirfenidone combined with immunosuppressant therapy in connective tissue disease-associated interstitial lung disease: a 24-week prospective controlled cohort study. Front Med 2022; 9: 871861. DOI: https://doi.org/10.3389/fmed.2022.871861
Distler O, Highland KB, Gahlemann M, Azuma A, Fischer A, Mayes MD, et al. Nintedanib for systemic sclerosis-associated interstitial lung disease. N Engl J Med 2019; 380: 2518-28. DOI: https://doi.org/10.1056/NEJMoa1903076
Raghu G, Montesi SB, Silver RM, Hossain T, Macrea M, Herman D, et al. Treatment of systemic sclerosis-associated interstitial lung disease: evidence-based recommendations. An official American Thoracic Society clinical practice guideline. Am J Respir Crit Care Med 2024; 209: 137-52. DOI: https://doi.org/10.1164/rccm.202306-1113ST
Sebastiani M, Lepri G, Iannone C, Bozzalla Cassione E, Guggino G, et al. Nintedanib in rheumatoid arthritis related interstitial lung disease: real-world safety profile and risk of side effects and discontinuation. J Rheumatol 2025; 52: 420-5. DOI: https://doi.org/10.3899/jrheum.2024-0976
Behr J, Prasse A, Kreuter M, Johow J, Rabe KF, Bonella F, et al. Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial. Lancet Respir Med 2021; 9: 476-86. DOI: https://doi.org/10.1016/S2213-2600(20)30554-3
Maher TM, Corte TJ, Fischer A, Kreuter M, Lederer DJ, Molina-Molina M, et al. Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Respir Med 2020; 8: 147-57. DOI: https://doi.org/10.1016/S2213-2600(19)30341-8
ISS. Trapianto di polmone. Available from: https://www.issalute.it/index.php/la-salute-dalla-a-alla-z-menu/t/trapianto-di-polmone#indicazioni.
Luppi F, Sebastiani M, Salvarani C, Bendstrup E, Manfredi A. Acute exacerbation of interstitial lung disease associated with rheumatic disease. Nat Rev Rheumatol 2022; 18: 85-96. DOI: https://doi.org/10.1038/s41584-021-00721-z
Wells A, Devaraj A, Renzoni EA, Denton CP. Multidisciplinary Evaluation in Patients with Lung Disease Associated with Connective Tissue Disease. Semin Respir Crit Care Med 2019; 40: 184-93. DOI: https://doi.org/10.1055/s-0039-1684020
How to Cite
1.
The Italian Society for Rheumatology guidelines for the treatment of patients with rheumatoid arthritis and interstitial lung disease. Reumatismo [Internet]. 2025 Nov. 10 [cited 2026 Jan. 25];. Available from: https://www.reumatismo.org/reuma/article/view/1865
Copyright (c) 2025 the Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
